middle.news
Telix Pharmaceuticals Posts $38.3M Profit on 22% Revenue Surge, Boosts R&D and Partners with Regeneron
8:40am on Thursday 20th of August, 2026 AEST
•
Healthcare
Read Story
Telix Pharmaceuticals Posts $38.3M Profit on 22% Revenue Surge, Boosts R&D and Partners with Regeneron
8:40am on Thursday 20th of August, 2026 AEST
Key Points
22% revenue growth to $477.3 million
Net profit after tax of $38.3 million versus prior loss
R&D spend up 52% to $123.8 million
Strategic collaboration with Regeneron for radiopharmaceutical therapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE